Fish oil reliably does one thing. The bigger claims are shakier.

If lowering triglycerides is relevant to you, fish oil has solid, consistent evidence behind it for exactly that. What it doesn’t have is strong evidence that a standard drugstore capsule meaningfully prevents heart attacks or strokes in the general population — a bigger claim that rode in on the back of the smaller, better-supported one.

Why this works, and where the evidence gets thinner

The triglyceride-lowering effect of omega-3 fatty acids is genuinely well established. Multiple meta-analyses consistently find meaningful reductions in circulating triglycerides with supplementation, and the mechanism is well understood — omega-3s reduce the liver’s production of triglyceride-carrying particles and increase their clearance from the blood. This is about as settled as supplement research gets.

The harder outcomes — actual heart attacks, strokes, and cardiovascular deaths — tell a messier story. A large meta-analysis of standard-dose omega-3 supplements found no statistically significant reduction in all-cause mortality, cardiac death, heart attack, or stroke, with one narrow exception at a specific higher dose. The two trials most responsible for omega-3’s reputation as a heart-protective supplement, JELIS and REDUCE-IT, both carry real methodological caveats worth knowing: JELIS was conducted in a Japanese population with an already very high background level of fish consumption, limiting how well it generalises to a typical Western diet, and REDUCE-IT used mineral oil as its placebo comparator — a choice later criticised because mineral oil itself may have mildly worsened outcomes in the comparison group, making the omega-3 arm look better by contrast than it might have against an inert placebo. Two more recent, large trials using combined EPA and DHA — the exact combination in most over-the-counter fish oil capsules — found no cardiovascular benefit, in contrast to the positive EPA-only findings, hinting that the benefit, if real, may be specific to high-dose EPA alone rather than the standard supplement most people actually buy.

There is a more specific, better-supported finding worth knowing: in people with diabetes, omega-3 supplementation — specifically the EPA component — was associated with a real reduction in cardiovascular risk in a meta-analysis pooling nearly 58,000 participants. This is a meaningfully different, narrower claim than “fish oil prevents heart disease in general,” and it’s the kind of specific, population-targeted finding that’s easy to lose in broader marketing.

How to do it

1. If you have elevated triglycerides specifically, fish oil is a reasonably well-evidenced option to discuss with a doctor — this is the use case with the strongest support.
2. Don’t take a standard over-the-counter capsule expecting broad heart attack or stroke prevention — the evidence for that specific outcome from typical doses is considerably weaker than popular belief suggests.
3. If cardiovascular risk reduction is genuinely the goal, that conversation belongs with a doctor who can weigh prescription-strength, EPA-specific formulations against your actual risk profile, rather than a general-purpose drugstore supplement.
4. Getting omega-3s from fatty fish (salmon, mackerel, sardines) a couple of times a week is a reasonable, well-supported dietary pattern independent of the supplement-specific controversy covered here.
5. If you’re already on blood thinners or have an irregular heart rhythm history, raise a high-dose fish oil supplement with a doctor first, given the bleeding and atrial fibrillation signals seen in some trials at higher doses.

Common mistakes

• Assuming “lowers triglycerides” and “prevents heart attacks” are the same claim. They’re related but distinct, and the evidence is considerably stronger for the first than the second.
• Treating JELIS and REDUCE-IT as clean, generalisable proof of broad cardiovascular benefit. Both have specific methodological features that limit how far their positive results should be extrapolated.
• Buying a standard EPA+DHA capsule expecting the EPA-only trial results. The two more recent large trials using the EPA+DHA combination — what’s actually in most supplements — were negative.
• Ignoring the diabetes-specific finding as if it applies to everyone. It’s a real, useful result for a specific population, not a general population claim.
• Skipping a doctor conversation if you’re on blood thinners. The bleeding and heart rhythm signals at higher doses are a genuine, not hypothetical, safety consideration.

What should change

If you’re taking fish oil for triglycerides specifically, expect a measurable reduction within four to eight weeks, trackable with a standard blood lipid panel. Don’t expect a noticeable change in cardiovascular risk you could feel or measure directly — that outcome, where it exists at all, plays out over years and is specific to particular populations and doses, not something a standard supplement reliably delivers to everyone.

Your next step

If cardiovascular risk more broadly is what you’re actually trying to manage, the article on the alcohol and heart health myth covers a related area where the popular health narrative has moved further from the current evidence than most people realise.